The effect of SGLT2 inhibitor on renal anemia in patients with moderate to severe chronic kidney disease and diabetes

SGLT2 inhibitor therapy leads to a small but significant increase in hemoglobin level in patients with diabetes, including those with moderate to severe CKD.